Ann: Completion of Rights Offering, page-2

Some positive comments from Dr. Juan in latest ann.

Dr. Juan Carlos Aragón, CEO of Visioneering, commented, “We greatly appreciate the support of ThorneyInvestment Group, our largest CDI holder, and many of our current investors for participating in this capitalraise. I joined Visioneering in early October hopeful that the impending announcement of the PROTECTClinical Trial results would be favorable. As we announced on October 12th at the American Academy ofOptometry meeting in New Orleans, the preliminary one-year results were very positive, as they wereconsistent with those of the only treatment approved by the U.S. Food and Drug Administration (FDA) formyopia progression control. These results have driven increased interest from Eye Care Practitioners andpotential strategic partners across the globe. I’m very excited about the opportunities that lie ahead for theCompany and hope to reward our investors for continuing to invest in the future of the Visioneering.”

Even a small uplift in interest from US ECP's would be significant.

Maybe now with 1 year data out, Menicon and others are better placed to look at a takeover as well.